The Valley Desk

NCT06208150 · Interventional trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Overall registry status Active not recruiting

Phase 3

Conditions Multiple Myeloma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov